Sanofi buys Genzyme (2011)
Sanofi acquired Genzyme, the rare disease drugmaker whose enzyme therapies had turned Gaucher disease from a fatal diagnosis into a manageable one. The deal brought Sanofi a pipeline of experimental compounds, including a glucosylceramide synthase inhibitor that had not yet been tested in patients.
Sanofi gained a rare disease business and a set of unproven molecules it spent years evaluating against different disorders.
The compound failed in Parkinson's disease, a rare kidney condition, GM2 gangliosidosis and Fabry disease before succeeding in Type 3 Gaucher.
The drug approved this month is a 15-year-old inheritance, not a fresh discovery.
